申请人:Beijing Hanmi Pharmaceutical Co., Ltd.
公开号:EP3336091A1
公开(公告)日:2018-06-20
The present invention relates to a compound inhibiting the activity of an IRAK4 kinase, a pharmaceutical composition thereof, a use thereof in preparing drugs, a method in which same is used for inhibiting the activity of the IRAK4 kinase and a method in which same is used for treating and/or preventing IRAK4 kinase mediated diseases or conditions in mammals (particularly humans). The compound has a structural formula I.
本发明涉及一种抑制IRAK4激酶活性的化合物、其药物组合物、其在制备药物中的用途、其用于抑制IRAK4激酶活性的方法以及其用于治疗和/或预防哺乳动物(特别是人类)中IRAK4激酶介导的疾病或病症的方法。该化合物具有结构式 I。